|
|
发表于 24-10-2020 09:35 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | HO WAH GENTING BERHAD (HWGB OR THE COMPANY)AGREEMENT ENTERED INTO BETWEEN TWIN OXIDE SOUTHEAST ASIA SDN BHD AND DVIRIA NANO TECH SDN BHD (FORMERLY KNOWN AS REX ORIENTAL SDN BHD), A WHOLLY OWNED SUBSIDIARY OF HWGB | INTRODUCTION The Board of Directors of the HWGB wishes to announce that its wholly owned subsidiary, Dviria Nano Tech Sdn Bhd (formerly known as Rex Oriental Sdn Bhd) (“Dviria”) had on 6 July 2020 entered into an agreement with Twin Oxide Southeast Asia Sdn Bhd (“Twin Oxide”) (herein after known as the “Parties”) for the appointment of Dviria by Twin Oxide on an exclusive basis to market, promote, distribute and sell TwinOxide®, a transportable non-explosive two-component chlorine dioxide (“Product”) in Malaysia and Indonesia (“Territory”) for a term of five (5) years, extendable for an additional five (5) years by the Parties mutual agreement in writing (“Agreement”).
The Product is an eco-friendly product that generates chlorine dioxide solution for application as disinfectant for industrial water treatment, livestock, horticulture, oil & gas, food & beverages, meat & poultry, fishing industry, commercial & institutional, recreation & leisure, marine, pulp & industry, textile & desalination and general healthcare purposes.
ABOUT DVIRIA Dviria was incorporated on 1 August 2013 under the Companies Act, 1965. The paid-up capital is RM400,000 with 400,000 ordinary shares in issued. The principal activities of Dviria is to carry on in the business in sanitising and disinfecting machines, equipment, apparatus including the sanitising, disinfecting agents, raw materials, products and parts.
ABOUT TWIN OXIDE Twin Oxide with its principal place of business at No. 221, A4-2-7, Solaris Dutamas, No. 1, Jalan Dutamas 1, Kuala Lumpur 50480 Malaysia was incorporated on 26 April 2018 in Malaysia. The issued share capital is RM100 with 100 ordinary shares in issued. The directors of TWIN OXIDE are Corey Brandon Adams, Emily Elizabeth Tan, and Alfie Jonathan Tan. The shareholders of Twin Oxide are Tan Hock Siang (1%), Corey Brandon Adams (35%), Emily Elizabeth Tan (30%), and Alfie Jonathan Tan (34%). Twin Oxide is principally engaged in export and import of chemical products. Whilst Twinoxide International B.V., a company incorporated in The Netherlands and having its principal place of business at De Tongelreep 17, NL-5684 PZ Best, The Netherlands (“TwinOxide INT”) is the exclusive worldwide license holder, producer and distributor for the Product. Twin Oxide is the authorized distributor in South East Asia for the Product.
SALIENT TERMS OF AGREEMENT Consideration a) Twin Oxide appoints Dviria on an exclusive basis to market, promote, distribute and sell the Product to end consumer, reseller, agent and distributor (“Retail”) in the Territory and Dviria agrees to accept such appointment in accordance with the terms and conditions of the Agreement. b) Twin Oxide shall have no right to sell the Product to any other person, company or entity, be it official or unofficial, in Retail in the Territory.
Term a) This Agreement shall be effective as of the date hereof and shall continue in force for an initial term of five (5) years but may be extended for an additional five (5) years by the Parties mutual agreement in writing.
Pricing a) It is agreed between the Parties that Dviria shall purchase the Product from Twin Oxide at a pre-determined price for the duration of this Agreement. b) The Parties may mutually agree to adjust the Purchase Price. c) The purchase order by Dviria for the purchase of the Product shall reflect the quantity, date, place and method of delivery of the Product to Dviria. d) In the event of any complaint vis-à-vis the Product by any retailers, Twin Oxide shall assist Dviria in its explanation to the customer. e) Twin Oxide shall deliver the Product to Dviria in accordance with the delivery schedule.
Termination Either Party may terminate this Agreement by written notice to the other Party: - in the event that Twin Oxide fails to deliver the Products to Dviria in accordance with the delivery schedule;
- in the event that the other Party breaches this Agreement which is not capable of remedy or if capable of remedy, fails to remedy that breach within thirty (30) days from the date of notification by the injured Party;
- in the event that the other Party makes an assignment for the benefit of creditors, commits an act of bankruptcy or a winding-up petition is filed against him and such petition is not discharged within thirty (30) days; or
- in the event that a receiver, receiver and manager, official manager, provisional liquidator, liquidator or like official is appointed over the whole or a substantial part of the undertaking or property of the other Party.
RATIONALE The Agreement and the Appointment enables the Group to participate in the nation’s efforts to contain the further spread of COVID-19 and other bacteria and viruses through the supply of disinfectant solution to the public and are expected to contribute positively to the financial performance of the Group.
FINANCIAL EFFECTS The entering into the Agreement is not expected to have any immediate material effect on the earnings, net assets, gearing, share capital and substantial shareholders’ shareholdings of HWGB. However, the Appointment as exclusive distributor is expected to contribute positively to the earnings of HWGB for the financial year ending 31 December 2020.
RISK FACTORS The Company does not expect any material risk arising from the Agreement other than the normal operational risk associated with the Agreement, which the Company would take appropriate measures to minimise it.
APPROVAL REQUIRED The Agreement is not subject to the approval of HWGB’s shareholders and/or any regulatory authorities.
INTEREST OF DIRECTORS, MAJOR SHAREHOLDER AND/OR PERSONS CONNECTED TO THEM None of the directors, major shareholders and/or persons connected to them has any interest, whether direct or indirect, in the Agreement.
STATEMENT OF DIRECTORS The Board, having taken into consideration all aspects of the Agreement, is of the opinion that the Agreement is in the best interests of the Company.
DOCUMENT FOR INSPECTION The Agreement is available for inspection at the registered office of the Company at 1st Floor, Wisma Ho Wah Genting, No. 35, Jalan Maharajalela, 50150 Kuala Lumpur during normal business hours (except public holidays) for a period of three (3) months from the date of this announcement.
The announcement is dated 6 July 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 6-12-2020 08:58 AM
|
显示全部楼层
本帖最后由 icy97 于 31-5-2021 08:35 AM 编辑
Type | Reply to Query | Reply to Bursa Malaysia's Query Letter - Reference ID | IQL-07082020-00004 | Subject | MEMORANDUM OF AGREEMENT ENTERED INTO BETWEEN HWGB BIOTECH SDN BHD ("HWGB BIOTECH") AND E-MO BIOLOGY INC. ("EBI") | Description | MEMORANDUM OF AGREEMENT ENTERED INTO BETWEEN HWGB BIOTECH SDN BHD (HWGB BIOTECH) AND E-MO BIOLOGY INC. (EBI) | Query Letter Contents | We refer to your Company’s announcement dated 6 August 2020, in respect of the aforesaid matter.
In this connection, kindly furnish Bursa Securities with the following additional information for public release:- 1) Paid- up share capital of EBI. 2) Background information such as educational, nationality and past working experiences of Qiyi Xi, Wei Chen, Lily Chen and Yan Wang. 3) Filing dates for all 5 PPA as well as the process & procedures, estimated time required to formalise the patent application. 4) Further information on Group IV viruses and further elaboration on how the PPA will assist EBI in conducting the phase IV clinical trials referred to in item 5 below. 5) In relation to the Initial Investigational New Drug (“IND”) application submitted by EBI on 15 June 2020 (i.e. IND 23321) for phase IV clinical trials for new indications, please clarify what type of drugs were submitted to the United States Food and Drug Administration (“FDA”) for the IND application and when does EBI expect to receive the FDA results and approval. 6) In relation to the salient terms of the Memorandum, please clarify the following: (a) Under Conditions Precedent (“CP”): (i) 2.1(b) states the PPA will be assigned by the owners / inventors to EBI on terms agreeable to HWGB Biotech. In this respect, please provide the status of the assignment and the salient terms to be agreeable to HWGB Biotech; and (ii) 2.1(c) states “confirmation on collaboration / engagement of the relevant laboratories”. In this respect, please provide the list of relevant laboratories and the type of collaborations / engagements with these laboratories; (b) Under HWGB Biotech’s Entitlement: Please explain whether HWGB Biotech has the required and relevant expertise in the medical field to undertake the relevant production and distribution of the New Indication given HWGB Biotech will have all exclusive rights for the production, distribution and sale of the New Indication in Southeast Asia countries. In this regard, please provide the following additional information:- (i) details of the production facilities, including the location, production capacity and whether such facilities are subject to any government authorities’ approval / consent; and (ii) the distribution channel for the sale of the New Indication; (c) Apart from the Investment Sum, please state whether there is any other obligations and / or additional outlay by HWGB Biotech, and if so, to indicate the indicative amount. 7) In terms of approvals from the relevant authorities, please indicate whether HWGB Biotech has applied for the necessary approvals from the Southeast Asia countries and the status of the application. | The Board of Directors wishes to announce the additional information pertaining to the Memorandum Of Agreement entered into between HWGB Biotech Sdn Bhd and E-MO Biology Inc.
Please refer to the attached file for the additional information.
This announcement is dated 10 August 2020. |
Type | Announcement | Subject | OTHERS | Description | JOINT VENTURE AGREEMENT ENTERED INTO BETWEEN HWGB BIOTECH SDN BHD (FORMERLY KNOWN AS HWG CONSORTIUM SDN BHD), A WHOLLY-OWNED SUBSIDIARY OF HWGB, AND E-MO BIOLOGY INC. | Reference is made to the Company’s announcement dated 6 August 2020 and 10 August 2020 in relation to the Memorandum of Agreement entered into between HWGB Biotech Sdn Bhd and E-Mo Biology Inc. on 6 August 2020 (“MOA”). Under the terms of the MOA, the Parties shall enter into a definitive agreement for the collaboration.
In relation to the above, the Board of Directors of HWGB wishes to announce that its wholly-owned subsidiary, HWGB Biotech Sdn Bhd (“HWGB BIOTECH”) (formerly known as HWG Consortium Sdn Bhd) had on 14 August 2020 entered into a joint venture agreement (“JV Agreement”) (“JV”) with E-MO BIOLOGY INC. (“EBI”). The JV is for HWGB BIOTECH to collaborate with EBI, whereby EBI shall undertake phase IV clinical trials for a new indication which proposes the use of existing poliomyelitis virus vaccines for prevention of the Diseases (as hereinafter defined) and the research and development, testing, registration, commercialization and other activities relating to the Patents (as hereinafter defined) for the purposes of treating infectious disease, including vaccines, immunological treatment, diagnostic product development and any similar treatments against the Severe Acute Respiratory Syndrome Coronavirus pandemic and other relevant diseases including but not limited to new indications which proposes the use of all types of existing poliomyelitis virus vaccines for prevention of COVID-19 (the “Project”) and whereby HWGB BIOTECH shall invest in the Project.
Please refer to the attached file for the details of the announcement.
This announcement is dated 14 August 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3077847
Type | Announcement | Subject | OTHERS | Description | HO WAH GENTING BERHAD (HWGB OR THE COMPANY)UPDATE ON THE JOINT VENTURE BETWEEN HWGB BIOTECH SDN BHD (FKA HWG CONSORTIUM SDN BHD) AND E-MO BIOLOGY INC. | (Unless otherwise stated or redefined, all abbreviations and definitions used herein shall have the same meanings as those used in the Company's announcement dated 14 August 2020)
Reference is made to the Company’s announcement dated 14 August 2020, whereby E-MO Biology Inc. (“EBI”) shall undertake phase IV clinical trials for a new indication which proposes the use of existing poliomyelitis virus vaccines for prevention of the Diseases and the research and development, testing, registration, commercialization and other activities relating to the patents for the purposes of treating infectious disease, including vaccines, immunological treatment, diagnostic product development and any similar treatments against the Severe Acute Respiratory Syndrome Coronavirus pandemic and other relevant diseases including but not limited to new indications which proposes the use of all types of existing poliomyelitis virus vaccines for prevention of COVID-19 (the “Project”).
The Company had on 18 September 2020 received updates from EBI that it had entered into the few agreements in relation to the Project. Kindly refer to the attach file for the details of the updates.
This announcement is dated 18 September 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3089227
Type | Announcement | Subject | OTHERS | Description | HO WAH GENTING BERHAD (HWGB OR THE COMPANY) UPDATE ON THE JOINT VENTURE BETWEEN HWGB BIOTECH SDN BHD (FKA HWG CONSORTIUM SDN BHD) AND E-MO BIOLOGY INC. | Unless otherwise defined, the abbreviations and definitions used in the announcement dated 14 August 2020 shall apply herein.
Reference is made to the Company’s announcement dated 14 August 2020, whereby E-MO Biology Inc. (“EBI”) shall undertake phase IV clinical trials for a new indication which proposes the use of existing poliomyelitis virus vaccines for prevention of the Diseases and the research and development, testing, registration, commercialization and other activities relating to the patents for the purposes of treating infectious disease, including vaccines, immunological treatment, diagnostic product development and any similar treatments against the Severe Acute Respiratory Syndrome Coronavirus pandemic and other relevant diseases including but not limited to new indications which proposes the use of all types of existing poliomyelitis virus vaccines for prevention of COVID-19.
The Board of Directors of HWGB wishes to announce that the Company, had on even date, received update from EBI that it had obtained approval from Advarra Inc., on the protocol in conducting a research study on the immune response induced by poliovirus vaccine booster that cross-reacts with Severe Acute Respiratory Syndrome Coronavirus.
For information purposes, Advarra Inc. is an institutional review board (“IRB”) registered with FDA. Under FDA regulations, an IRB is an appropriately constituted group that has been formally designated to review and monitor biomedical research involving human subjects. In accordance with FDA regulations, an IRB has the authority to approve, require modifications in (to secure approval), or disapprove research. This group review serves an important role in the protection of the rights and welfare of human research subjects.
For avoidance of doubt, this is IRB approval on the protocol only. Principal investigators for each site must complete a separate site submission to obtain IRB approval notice allowing them to conduct the study.
Further announcement on the development of the above matter shall be made in due course.
This announcement is dated 14 October 2020. |
Type | Announcement | Subject | OTHERS | Description | UPDATE ON JOINT VENTURE BETWEEN HWGB BIOTECH SDN BHD (FKA HWG CONSORTIUM SDN BHD) AND E-MO BIOLOGY INC. - REPLY FROM FDA ON SUBMISSION FOR APPROVAL TO COMMENCE PHASE IV CLINICAL TRIAL ON USE OF EXISTING POLIOMYELITIS VIRUS VACCINES FOR PREVENTION OF COVID-19 | Unless otherwise defined, the abbreviations and definitions used in the announcements dated 6, 10, 14 and 28 August 2020, 5 and 14 October 2020 (“Announcements”) shall apply herein.
Reference is made to the Company’s Announcements, whereby E-MO Biology Inc. (“EBI”) shall undertake phase IV clinical trials for a new indication which proposes the use of existing poliomyelitis virus vaccines for prevention of the Diseases (as hereinafter defined) and the research and development, testing, registration, commercialization and other activities relating to the patent for the purposes of treating infectious disease, including vaccines, immunological treatment, diagnostic product development and any similar treatments against the Severe Acute Respiratory Syndrome Coronavirus pandemic and other relevant diseases (“Diseases”) including but not limited to new indications which proposes the use of all types of existing poliomyelitis virus vaccines for prevention of COVID-19.
The Board of Directors is pleased to announce that the Company, had on 28 October 2020, received update from EBI that it had obtained approval from U.S. Food and Drug Administration (FDA) to conduct phase IV clinical trials for a new indication which proposes the use of existing poliomyelitis virus vaccines for prevention of the Diseases. With the approval EBI can commence its Phase IV clinical research study on the effectiveness of poliomyelitis virus vaccine for prevention of the Diseases.
The Company will update on the on-going progress accordingly.
|
Type | Announcement | Subject | OTHERS | Description | SUPPLEMENTAL JOINT VENTURE AGREEMENT ENTERED INTO BETWEEN HWGB BIOTECH SDN BHD (HWGB BIOTECH) (FORMERLY KNOWN AS HWG CONSORTIUM SDN BHD), A WHOLLY-OWNED SUBSIDIARY OF HO WAH GENTING BERHAD AND E-MO BIOLOGY INC. (EBI) (SUPPLEMENTAL JVA) | Unless otherwise defined, the abbreviations and definitions used in the announcements dated 6, 10, 14 and 28 August 2020, 5 and 14 October 2020 (“Announcements”) shall apply herein.
Reference is made to the announcement on the joint venture agreement dated 14 August 2020 (“JV Agreement”) entered into between HWGB Biotech and EBI (collectively, the “Parties”) for the collaboration between both Parties, whereby EBI shall undertake phase IV clinical trials for a new indication which proposes the use of existing poliomyelitis virus vaccines for prevention of the Diseases (as hereinafter defined) and the research and development, testing, registration, commercialization and other activities relating to the patents for the purposes of treating infectious disease, including vaccines, immunological treatment, diagnostic product development and any similar treatments against the SARS-CoV-2 pandemic and other relevant diseases (the “Diseases”) including but not limited to new indications which proposes the use of all types of existing poliomyelitis virus vaccines for prevention of COVID-19 (“Vaccine”) (the “Project”) and whereby HWGB Biotech shall invest in the Project.
EBI had on 30 October 2020, informed HWGB Biotech that Dr. Qiyi Xie had filed for a new patent application in lieu of the 5 provisional patent applications that was filed earlier and as announced on 14 August 2020, in view of the following:
a. The new patent application emphasizes on the intellectual property protection of a new vaccine targeting COVID-19 for both new compositions and new medical applications. Thus, it covers vaccination technology advanced from the ones covered by the earlier five provisional patent applications;
b. New patent application is based on recent observations to boost the human immune system against COVID-19 by using well-developed oral polio vaccines; and
c. The new patent application with the specific immunological method and under the condition of “general vaccine strategy” which does not change its nature is expected to simplify applications for regulatory market access license.
This new patent application has since been assigned to EBI on 30 October 2020.
Upon deliberation, HWG Biotech and EBI had on even date entered into a supplemental joint venture agreement (“Supplemental JVA”) to vary the terms and conditions of the JV Agreement (collectively referred to as the “Agreements”) in line with the intention to expedite the Project to overcome the pandemic by focusing on FDA approved polio vaccine application.
This announcement is dated 2 November 2020.
Please refer to the attached for details of the announcement |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3102052
Type | Announcement | Subject | OTHERS | Description | SECOND SUPPLEMENTAL JOINT VENTURE AGREEMENT ENTERED INTO BETWEEN HWGB BIOTECH SDN BHD (HWGB BIOTECH) (FORMERLY KNOWN AS HWG CONSORTIUM SDN BHD), A WHOLLY-OWNED SUBSIDIARY OF HO WAH GENTING BERHAD (HWGB) AND E-MO BIOLOGY INC. (EBI) (SECOND SUPPLEMENTAL JVA) | Unless otherwise defined, the abbreviations and definitions used in the announcements dated 14 August 2020 and 2 November 2020 (“Announcements”) shall apply herein.
1. INTRODUCTION HWGB wishes to announce that HWGB Biotech had on 17 November 2020 entered into a Second Supplemental JVA to include amongst others, an additional patent application recently assigned to EBI.
2. DETAILS OF THE SECOND SUPPLEMENTAL JVA On 14 August 2020, the Board of Directors of HWGB announced that its wholly-owned subsidiary, HWGB Biotech had on even date entered into a joint venture agreement (“JV Agreement”) (“JV”) with EBI. The JV is for HWGB Biotech to collaborate with EBI, whereby EBI shall undertake phase IV clinical trials for a new indication which proposes the use of existing poliomyelitis virus vaccines for prevention of the Diseases and the research and development, testing, registration, commercialization and other activities relating to the Patents for the purposes of treating infectious disease, including vaccines, immunological treatment, diagnostic product development and any similar treatments against the Severe Acute Respiratory Syndrome Coronavirus pandemic and other relevant diseases including but not limited to new indications which proposes the use of all types of existing poliomyelitis virus vaccines for prevention of COVID-19 and whereby HWGB Biotech shall invest in the Project.
Subsequently, the Parties had on 2 November 2020 entered into a supplement joint venture agreement (“Supplemental JVA”) in view that a new patent application had been filed by Dr. Qiyi Xie in lieu of the 5 provisional patent applications as stated in the previous JV Agreement.
Further to the Supplemental JVA, Dr. Qiyi Xie (as sole inventor) had on 16 November 2020 assigned a further patent application to EBI. In light thereof, the Parties had on 17 November 2020 entered into a second supplemental joint venture agreement to include the newly assigned patent application and all future patent(s) application(s) filed or assigned to EBI relating to the Vaccine, for the purposes of treating and/or preventing the Diseases and/or the Project to Exhibit A of the JV Agreement.
2.1 Revision of Exhibit A
The Parties agreed that the following shall be added to the Exhibit A of the Supplemental JVA:
“2. Application Number: 17098449. Title of Invention: VACCINATION AGAINST CORONAVIRUS WITH POLIOMYELITIS VACCINE. Inventor/Applicant Name: Qiyi Xie. Application Type: Utility under 35 USC 111(a).”
“3. Such other patent application(s) to be filed (whether provisional or non-provisional) and/or patent(s) applications previously filed, for invention(s) relating to Vaccine, for the purposes of treating and/or preventing the Diseases and/or in relation to the Project which has been applied for and/or assigned to EBI, existing now or in the future.”
3. DOCUMENTS AVAILABLE FOR INSPECTION The Second Supplemental JVA signed by both Parties is available for inspection at the registered office of the Company at Wisma Ho Wah Genting, 1st Floor, No. 35, Jalan Maharajalela, 50150 Kuala Lumpur during normal office hours on Mondays to Fridays (except for public holidays) for a period of three (3) months from the date of this announcement.
This announcement is dated 19 November 2020.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 1-1-2021 08:21 AM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Jun 2020 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Jun 2020 | 30 Jun 2019 | 30 Jun 2020 | 30 Jun 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 53,267 | 62,027 | 101,442 | 99,370 | | 2 | Profit/(loss) before tax | -1,699 | 884 | 255 | 128 | | 3 | Profit/(loss) for the period | -1,870 | -174 | -702 | -1,184 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | -1,869 | -174 | -700 | -1,184 | | 5 | Basic earnings/(loss) per share (Subunit) | -0.40 | -0.05 | -0.15 | -0.34 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.0800 | 0.1000
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 8-1-2021 08:42 AM
|
显示全部楼层
icy97 发表于 11-8-2020 08:30 AM
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3057558
Type | Announcement | Subject | MULTIPLE PROPOSALS | Description | HO WAH GENTING BERHAD ("HWGB" OR THE "COMPANY")- PROPOSED PLACEMENT OF IRREDEEMABLE CONVERTIBLE PREFERENCE SHARES;- PROPOSED DEBT SETTLEMENT; AND- PROPOSED AMENDMENTS (COLLECTIVELY, THE "PROPOSALS") | (Unless otherwise stated or redefined, all abbreviations and definitions used herein shall have the same meanings as those used in the Company's annoucement dated 10 June 2020 in relation to the Proposals)
Reference is made to the announcement dated 10 June 2020 whereby M&A Securities had, on behalf of the Board, announced that the Company proposes to undertake amongst others the Proposed Placement of ICPS and as a consequential proposal, the Proposed Amendments.
On behalf of the Board, M&A Securities wishes to announce that the Company had on 3 September 2020 mutually agreed with HWGH and the other Subscribers respectively, to terminate the Subscription Agreements.
As such, the Company will not be proceeding with the Proposed Placement of ICPS and the Proposed Amendments. The Proposed Debt Settlement will remain unchanged.
Kindly refer to the attachment for further information.
This annnoucement is dated 3 September 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3085370
|
|
|
|
|
|
|
|
|
|
|
|
发表于 11-1-2021 08:46 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | MEMORANDUM OF UNDERSTANDING ENTERED INTO BETWEEN HWGB BIOTECH SDN BHD AND XINKEXIAN (BEIJING) BIOTECHNOLOGY CO., LTD | The Board of Directors of the Ho Wah Genting Berhad (“HWGB” or “the Company”) wishes to announce that its wholly owned subsidiary, HWGB Biotech Sdn Bhd (Formerly known as HWG Consortium Sdn Bhd) had on 9 September 2020 entered into a Memorandum of Understanding with Xinkexian (Beijing) Biotechnology Co., Ltd (“XKX”) to explore the possibility of appointing XKX as a non-exclusive manufacturer to produce the Vaccines upon successful completion of R&D and upon approval from the United States Food and Drug Administration.
Kindly refer to the attach file for further information.
This announcement is dated 9 September 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3086706
|
|
|
|
|
|
|
|
|
|
|
|
发表于 19-1-2021 08:42 AM
|
显示全部楼层
Date of change | 22 Sep 2020 | Name | MR BERNARD LIM SOON CHIANG | Age | 48 | Gender | Male | Nationality | Malaysia | Designation | Non Executive Chairman | Directorate | Independent and Non Executive | Type of change | Resignation | Reason | Personal Reason | Details of any disagreement that he/she has with the Board of Directors | No | Whether there are any matters that need to be brought to the attention of shareholders | No |
QualificationsNo | Qualifications | Major/Field of Study | Institute/University | Additional Information | | 1 | Professional Qualification | Accountancy Association of Chartered Certified Accountants (“ACCA”) | Emile Woolf, London | |
Working experience and occupation | Mr. Bernard Lim Soon Chiang has 27 years of working experience in the areas of accounting, finance and taxation, the past 21 years of which were in the Construction and Property Development industry.He began his career with Messrs Ernst & Young as Executive and subsequently, Hong Leong Bank Berhad where he was attached to the Accounting, Treasury and Planning Division. He then moved into the construction sector through his involvement with the construction arm of Tanming Berhad where he spearheaded the Finance Department and rose through the ranks to become the Group Financial Controller of Tanming Berhad.Mr. Bernard Lim Soon Chiang then joined a subsidiary of Gabungan AQRS Bhd as Finance Director in 2002 and was subsequently promoted as the Chief Financial Officer of Gabungan AQRS Bhd Group in 2012. He was instrumental in spearheading Gabungan AQRS Bhds Initial Public Offering which took place in 2012. He left Gabungan AQRS Bhd on 28 December 2017.He is currently a principal consultant in BQIE Consultancy Sdn Bhd, a consulting company which offers services in relation to business strategy, corporate restructuring, fund raising and etc. |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 17-2-2021 09:51 AM
|
显示全部楼层
本帖最后由 icy97 于 25-3-2021 08:18 AM 编辑
Type | Announcement | Subject | OTHERS | Description | HO WAH GENTING BERHAD (HWGB OR THE COMPANY) HWGB MEDICAL DEVICES & SUPPLIES SDN BHD (FORMERLY KNOWN AS HWG DUTY FREE SDN. BHD) (HWGB MEDICAL DEVICES & SUPPLIES), A SUBSIDIARY OF HWGB, OBTAINED CERTIFICATION ON GOOD DISTRIBUTION PRACTICE FOR MEDICAL DEVICES | The Board of Directors of HWGB wishes to announce that HWGB Medical Devices & Supplies had, on 1 Oct 2020, received official notification from Genuine Diamond Sdn Bhd, an approved certification body by Medical Device Authority (“MDA”) which is part of Malaysia Ministry of Health body, that HWGB Medical Devices & Supplies had passed the initial audit and was issued the Good Distribution Practice for Medical Devices Certificate of Conformity, which allows HWGB Medical Devices & Supplies to act as an authorised representative, for the import, storage and handling, warehousing, distribution (including transportation), installation, testing and commissioning (including required facilities), maintenance and calibration (including required facilities) and documentation (including traceability of medical devices) of medical devices, specifically in electro mechanical medical devices, hospital hardware, in-vitro diagnostics devices, single-use devices, complementary therapy devices and laboratory equipment. The certificate was dated 28 September 2020 and will expire on 27 September 2023.
This is the first step in order for HWGB Medical Devices & Supplies to be able to be legally allowed to import and distribute medical devices.
The next immediate step is for HWGB Medical Devices & Supplies to submit for the MDA establishment license which will ensure that HWGB Medical Devices & Supplies is in full compliance with the Malaysia Ministry of Health and the MDA's requirements for a company to be a licensed distributor of medical devices.
HWGB will update on the on-going progress of the aforesaid application process accordingly.
This announcement is dated 2 October 2020.
|
Type | Announcement | Subject | OTHERS | Description | HWGB MEDICAL DEVICES & SUPPLIES SDN BHD (Formerly known as HWG Duty Free Sdn Bhd) (HWGB MEDICAL DEVICES & SUPPLIES), A SUBSIDIARY OF THE COMPANY, OBTAINED ESTABLISHMENT LICENSE FROM MEDICAL DEVICE AUTHORITY (MDA) FOR MEDICAL DEVICES | Unless otherwise defined, the abbreviations and definitions used in the announcement dated 2 October 2020 shall apply herein.
Further to the Company’s announcement released on 2 October 2020, the Board of Directors wishes to update that HWGB Medical Devices & Supplies had today obtained approval from MDA for the establishment license application. With the establishment license, HWGB Medical Devices & Supplies is now able to act as a local authorised representative, for the import, storage and handling, warehousing, distribution (including transportation), installation, testing and commissioning (including required facilities), maintenance and calibration (including required facilities) and documentation (including traceability of medical devices) of medical devices, specifically in electro mechanical medical devices, hospital hardware, in-vitro diagnostics devices, single-use devices, complementary therapy devices and laboratory equipment approved by Malaysia Ministry of Health.
This announcement is dated 30 October 2020. |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 1-3-2021 08:36 AM
|
显示全部楼层
Type | Reply to Query | Reply to Bursa Malaysia's Query Letter - Reference ID | IQL-09102020-00002 | Subject | Article Entitled: "Malaysian digital bank forges partnership with UK-based lender" | Description | Clarification on Article entitled: "Malaysian digital bank forges partnership with UK-based lender" | Query Letter Contents | We refer to the above article appearing in New Straits Times, Page 28, on Friday,9 October 2020, a copy of which is enclosed for you reference.
In particular, we would like to draw your attention to the underlined sentence(s) which is/are reproduced as follows :-
(a) "Digital Investment Bank Ho Wah Genting Investment Bank has inked a partnership with Nevis International Bank & Trust, a fully-regulated banking group with a deep British heritage"
In accordance with Bursa Securities' Corporate Disclosure Policy, kindly furnish Bursa Securities with an announcement for public release confirming or denying the above reported article in particular the underlined sentences after due and diligent enquiry with all the directors, major sharesholders and all such other person reasonably familiar with the matters about which the disclosure is to made in this respect. In the event you deny the above reported sentences or any other part of the article, you are required to set forth facts sufficient to support the same. | We refer to the article appearing in New Straits Times, page 28, on Friday, 9 October 2020.
After clarification sought with the founder of HWGB, the Board of Directors of Ho Wah Genting Berhad (“HWGB”) wishes to clarify that: - Ho Wah Genting Investment Bank as referred to in the Article is Ho Wah Genting Investment Bank (Labuan) P.L.C., an investment bank incorporated in Labuan (“HWIB”);
- HWIB is not a subsidiary nor an associate company of HWGB; and
- HWIB is a privately held venture related to the founder of HWGB.
This announcement is dated 9 October 2020. |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 15-3-2021 06:54 AM
|
显示全部楼层
本帖最后由 icy97 于 2-8-2021 07:15 AM 编辑
Notice of Interest Sub. S-hldr (Section 137 of CA 2016)Particulars of Substantial Securities HolderName | ZY SALES & DISTRIBUTION SDN BHD | Address | V02-08-12, Velocity Office 2
Lingkaran SV, Sunway Velocity
Kuala Lumpur
55100 Wilayah Persekutuan
Malaysia. | Company No. | 1325721-U | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | ORDINARY SHARES | Name of registered holder | ZY SALES & DISTRIBUTION SDN BHD | Address of registered holder | V02-08-12, Velocity Office 2, Lingkaran SV, Sunway Velocity, 55100 Kuala Lumpur |
| Date interest acquired & no of securities acquired | Date interest acquired | 22 Oct 2020 | No of securities | 90,000,000 | Circumstances by reason of which Securities Holder has interest | Acquisition | Nature of interest | Direct Interest |  | | Total no of securities after change | Direct (units) | 90,000,000 | Direct (%) | 17.087 | Indirect/deemed interest (units) |
| | Indirect/deemed interest (%) |
| | Date of notice | 22 Oct 2020 | Date notice received by Listed Issuer | 22 Oct 2020 |
Name | HO WAH GENTING HOLDING SDN BHD | Address | Wisma Ho Wah Genting 1st Floor,
No. 35, Jalan Maharajalela,
Kuala Lumpur
50150 Wilayah Persekutuan
Malaysia. | Company No. | 475995-U | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | ORDINARY SHARES |
Details of changesNo | Date of change | No of securities | Type of Transaction | Nature of Interest | | 1 | 21 Oct 2020 | 20,000,000 | Disposed | Direct Interest | Name of registered holder | Ho Wah Genting Holding Sdn Bhd | Address of registered holder | Wisma Ho Wah Genting 1st Floor, No. 35, Jalan Maharajalela, 50150 Kuala Lumpur | Description of "Others" Type of Transaction | | | 2 | 22 Oct 2020 | 90,000,000 | Disposed | Direct Interest | Name of registered holder | Ho Wah Genting Holding Sdn Bhd | Address of registered holder | Wisma Ho Wah Genting 1st Floor, No. 35, Jalan Maharajalela, 50150 Kuala Lumpur | Description of "Others" Type of Transaction | |
Circumstances by reason of which change has occurred | DISPOSAL OF SHARES | Nature of interest | Direct Interest | Direct (units) | 149,951,065 | Direct (%) | 28.47 | Indirect/deemed interest (units) |
| | Indirect/deemed interest (%) |
| | Total no of securities after change | 149,951,065 | Date of notice | 22 Oct 2020 | Date notice received by Listed Issuer | 22 Oct 2020 |
Type | Announcement | Subject | OTHERS | Description | PT HO WAH GENTING (PT HWG), A WHOLLY-OWNED SUBSIDIARY OF HWGB, OBTAINED APPROVAL FROM MINISTRY OF HEALTH OF INDONESIA (MOH INDONESIA) (KEMENTERIAN KESEHATAN REPUBLIK INDONESIA) FOR MEDICAL DEVICES | The Board of Directors is pleased to announce that PT HWG had today obtained approval from MOH Indonesia to manufacture surgical face masks, COVID-19 rapid test cassettes and liquid chemical sterilants / high level disinfectants subject to the following conditions: - Production under the supervision of Ariston Ginting, being the registered pharmacist of PT HWG at all times;
- To apply Guidelines of Good Manufacturing Practices for Medical Devices in terms of the facilities documentation and hygiene sanitation;
- To furnish yearly production result report to the Director General of the Pharmacy and Medical Devices, copied to the provincial and district health office by location;
- Testing its products by an accredited or approved laboratory for carrying out analysis and inspection on the production material used and the final product; and
- Carry out the production of medical peripheral equipment in accordance with the regulation of Ministry of Health No. 1189/MENKES/PER/VIII/2010, in relation to the production of medical devices and household health supplies and other related regulations.
The approval is valid for (1) one year and it is compulsory for PT HWG to comply with the statutory provisions. Any amendments deemed appropriate has to be made within the stipulated timeframe.
This announcement is dated 9 November 2020. |
SUMMARY OF KEY FINANCIAL INFORMATION
30 Sep 2020 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Sep 2020 | 30 Sep 2019 | 30 Sep 2020 | 30 Sep 2019 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 96,092 | 47,222 | 197,534 | 146,592 | | 2 | Profit/(loss) before tax | 2 | -379 | 257 | -251 | | 3 | Profit/(loss) for the period | -782 | -722 | -1,484 | -1,906 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | -773 | -722 | -1,473 | -1,906 | | 5 | Basic earnings/(loss) per share (Subunit) | -0.20 | -0.21 | -0.30 | -0.55 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.0800 | 0.1000
|
Type | Announcement | Subject | OTHERS | Description | PROPOSED COLLABORATION ON COVID-19 VACCINE WITH MALAYSIAN GOVERNMENT | 1. INTRODUCTION
The Board of Directors (“Board”) of Ho Wah Genting Berhad (“HWGB” or the “Company”) is pleased to announce that its wholly-owned subsidiary, HWGB Biotech Sdn Bhd (formerly known as HWG Consortium Sdn Bhd) (“HWGB Biotech”) had today submitted a letter to the Ministry of Science, Technology and Innovation Malaysia (“MOSTI”) to seek the support from MOSTI on its research study and to explore potential collaboration on the distribution of the Covid-19 vaccine developed by E-Mo Biology Inc. (“EBI”) upon approval by US Food And Drug Administration being obtained.
2. INFORMATION ON MOSTI
MOSTI is a government agency that plays a pivotal role in helping with the Covid-19 vaccine development effort at international level. In March 2020, MOSTI had taken the initiative to be involved in the Coalition for Epidemic Preparedness Innovations (CEPI) and the participation as a coalition member which enabled Malaysia to gain access to vaccine development, technology transfer and new expertise, for local researchers.
3. RATIONALE
This potential collaboration with MOSTI will support HWGB Biotech’s participation in research study on the Covid-19 vaccine and it is also a positive step for HWGB Biotech efforts to plan for the distribution of EBI’s E-Mo Covid-19 Vaccine in Malaysia.
4. FINANCIAL EFFECTS
There will be no effect on the issued and paid-up share capital and the substantial shareholders’ shareholdings of HWGB, as it does not involve any issuance of new shares in HWGB.
4.1 EARNINGS AND EARNINGS PER SHARE (“EPS”)
Barring any unforeseen circumstances, any procurement agreements that arise from the collaboration with MOSTI is expected to contribute positively to the earnings and EPS of HWGB and its subsidiaries (“the Group”) in the future.
4.2 NET ASSETS (“NA”) AND GEARING
The collaboration is not expected to have any material effects on the NA and gearing of the Group for the financial year ending 31 December 2020.
5. APPROVALS REQUIRED
The distribution of Covid-19 vaccines is subject to and conditional upon approvals being obtained from the following local authorities:
a) Ministry of Health Malaysia; b) National Pharmaceutical Regulatory Agency; and c) And other relevant authorities and/or third parties, if required.
6. RISK FACTORS
HWGB does not expect any material risk other than the normal business and industry risks such as regulatory approvals of local authorities, logistics handling of the vaccines and competition.
7. DIRECTORS’ STATEMENT
Having considered all aspects of the collaboration, the Board of HWGB is of the opinion that this collaboration is in the best interest of the Group.
This announcement is dated 7 December 2020. |
Notice of Person Ceasing (Section 139 of CA 2016)Particulars of Substantial Securities HolderName | ZY SALES & DISTRIBUTION SDN BHD | Address | V02-08-12, Velocity Office 2
Lingkaran SV, Sunway Velocity
Kuala Lumpur
55100 Wilayah Persekutuan
Malaysia. | Company No. | 1325721-U | Nationality/Country of incorporation | Malaysia | Descriptions (Class) | Ordinary Shares | Name of registered holder | ZY SALES & DISTRIBUTION SDN BHD | Address of registered holder | V02-08-12, Velocity Office 2, Lingkaran SV, Sunway Velocity, 55100 Kuala Lumpur, Wilayah Persekutuan | Date of cessation | 04 Dec 2020 |
No of securities disposed | 68,000,000 | Circumstances by reason of which a person ceases to be a substantial shareholder | Disposal in the open market | Nature of interest | Direct Interest | | Date of notice | 07 Dec 2020 | Date notice received by Listed Issuer | 07 Dec 2020 |
Type | Announcement | Subject | OTHERS | Description | AUTHORISATION BY WENZHOU OJA BIOTECHNOLOGY CO. LTD. AS THE EXCLUSIVE DISTIBUTOR FOR ITS SARS-COV-2 NEUTRALISING ANTIBODY (NABS) DETECTION KIT, A POST VACCINATION TEST KIT IN MALAYSIA AND INDONESIA | The Board of Directors wishes to announce that Ho Wah Genting Berhad’s subsidiary, HWGB Medical Devices & Supplies Sdn Bhd (formerly known as HWG Duty Free Sdn Bhd) (“HWGB Medical Devices”) had on today received letters of authorisation, both dated 10 December 2020 from Wenzhou OJA Biotechnology Co. Ltd (“WOJA”), authorising HWGB Medical Devices as the exclusive distributor of its SARS-CoV-2 Neutralizing Antibody (NAbs) Detection Kit (A post vaccination test kit) (“Product”) in Malaysia and Indonesia respectively (“Authorisations”). The validity of the Authorisations is from 10 December 2020 to 9 December 2022.
Please refer to the attached file for the details of the Announcement.
This announcement is dated 11 December 2020. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3113078
Type | Announcement | Subject | OTHERS | Description | MEMORANDUM OF UNDERSTANDING FOR UTILISING THE HUB MARKETPLACE TO PROMOTE AND MARKET VARIOUS MEDICAL DEVICES AND PRODUCTS ENTERED INTO BETWEEN HWGB BIOTECH SDN BHD (FORMERLY KNOW AS HWG CONSORTIUM SDN BHD) (HWGB BIOTECH AND NIHAO GLOBAL CORPORATION LIMITED (NIHAO) | 1. INTRODUCTION
The Board of Directors of Ho Wah Genting Berhad (“HWGB” or “Company”) wishes to announce that its wholly-owned subsidiary HWGB Biotech, had on 18 December 2020 entered into a Memorandum of Understanding (“MOU”) with Nihao (herein after known as the “Parties”) to establish a basis of co-operation and collaboration between the Parties for the purposes of registering HWGB Biotech as supplier on “The Medical Products Hub” to promote and market medical devices and products sourced by HWGB Biotech, one of the main supplier authorization was received from Wenzhou OJA Biotechnology Co., Ltd (“WOJA”) on 10 December 2020 (“Collaboration”).
2. INFORMATION ON NIHAO
Nihao is a company incorporated and based in Hong Kong. Nihao provides personalised and specialised services to business that requires initiation and maintaining the traction within the Chinese market place. It has subsidiaries in Australia (Nihao Global Corporation Pty Ltd) and Mainland China (Beijing Nihao Advisory). Nihao also has a division referred to as ‘The Medical Products Hub’, which is a market place that provides an end-to-end solution for clients to purchase bulk medical supplies and equipment at wholesale rates for delivery anywhere in the world (“The Hub Marketplace”).
The directors of Nihao are Nigel Ian Blair, Li Jia Ni, Stephen Treanor and Richard Michael Parris. The shareholders of Nihao are Ticktop Limited (52%), Janus Limited (47%) and Christopher Ina Switzer (1%).
3. INFORMATION ON WOJA
WOJA was founded in April 2020 by Dr. Wang Jin Gu, who has more than 10 years of experience in in-vitro diagnostics field, as an extension of BIOSIC; a company that specializes in early cancer detection and disease diagnostic, WOJA was then formed to focus on the development of testing solutions for the SARS-CoV-2. Prior to the outbreak of the COVID-19 epidemic, the founders and the panel of medical experts had been working on perfecting methods to accurately and efficiently diagnose various diseases and viruses. The issued share capital of WOJA as at the date of this announcement stood at RMB5.0 million. The director of WOJA is Dr. Wang Jing Gu whilst the shareholders of WOJA are Dr. Wang Jin Gu (40%), Ye fen fen (20%), Xu Tao (20%) and Hangzhou Best Biotechnology Co., Ltd (20%).
4. SALIENT TERMS OF THE MOU
The salient terms of the MOU are, amongst others, as follows:
(i) HWGB Biotech is desirous of utilising “The Hub Marketplace” to promote and market various medical devices and products;
(ii) Nihao shall review and assess the applicable medical devices and products for approval to be listed on “The Hub Marketplace” and then submit the aforementioned medical devices and products to the World Health Organization (“WHO”) for accreditation and approval; and
(iii) HWGB Biotech shall, upon accreditation and approval by WHO on the medical devices and products, be registered as supplier on “The Hub Marketplace”.
5. RATIONALE OF THE MOU
HWGB Biotech is authorized by WOJA to act as its online market place and e-commerce website representative for the purposes of marketing, promoting and sale of its medical devices and products. With the Collaboration with Nihao, HWGB Biotech will be able to market and sell all medical devices and products its sourced from WOJA on “The Hub Marketplace” and expand market penetration globally.
6. DURATION OF THE MOU
The MOU remains valid and effective for twelve (12) months from the date of the MOU or terminated by the execution of a definitive agreement or such other agreement which shall then supersede the MOU. Early termination is allowed by mutual agreement in writing. In the event of termination, the term governing confidentiality and publicity of the MOU shall remain binding and enforceable notwithstanding the termination of the MOU.
7. FINANCIAL EFFECTS OF THE MOU
The MOU is not expected to have any material effect on the earnings per share, net assets per share, gearing, share capital and substantial shareholders’ shareholding of the Company for the financial year ending 31 December 2020. Should the business materialize, it is expected to contribute positively to the future earnings of the Group.
8. STATEMENT BY DIRECTORS
The Board of Directors of the Company, having taken into consideration all aspects of the MOU, is of the opinion that the MOU is in the best interest of HWGB Biotech and the Group.
9. APPROVALS REQUIRED
The MOU is not subject to the approval of the shareholders of the Company.
10. DOCUMENTS AVAILABLE FOR INSPECTION
The MOU is available for inspection at the Registered Office of the Company at 1st Floor, Wisma Ho Wah Genting, No. 35, Jalan Maharajalela, 50150 Kuala Lumpur during normal office hours on Mondays to Fridays (except for public holidays) for a period of three (3) months from the date of this announcement.
This announcement is dated 18 December 2020. |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 30-8-2021 08:38 AM
|
显示全部楼层
本帖最后由 icy97 于 10-9-2021 08:32 AM 编辑
Type | Announcement | Subject | OTHERS | Description | MEMORANDUM OF UNDERSTANDING FOR COLLABORATION TO MANUFACTURE AND PRODUCE IN VITRO DIAGNOSTIC PRODUCTS ENTERED INTO BETWEEN HO WAH GENTING BERHAD AND CHONGQING ISIA BIO-TECHNOLOGY CO., LTD (ISIA) | 1. INTRODUCTION The Board of Directors of Ho Wah Genting Berhad (“HWGB” or “Company”) wishes to announce that it had on 11 January 2021 entered into a Memorandum of Understanding (“MOU”) with ISIA (hereinafter known as the “Parties”) to establish a basis of co-operation and collaboration between the Parties for the purposes of manufacturing and producing in vitro products.
2. INFORMATION ON ISIA ISIA, founded in May 2016, is an innovative enterprise dedicated to the R&D, production, sales and service for reagents and instruments of in vitro diagnostic products. ISIA has a professional research team which has been developing and producing many new in vitro diagnostic products each year including products which covers infectious diseases, cardiovascular diseases, renal diseases, gastric diseases, autoimmune diseases, cancer, etc. The executive director of ISIA is Zhang Nianlin. The shareholders of ISIA are Shanghai Kang Nai Yin Enterprise Management Partnership (Limited Partnership) (55.77%), Gong Xiaojun (20.08%), Chongqing Saiyan Enterprise Management Partnership (Limited Partnership) (9.29%), Zhang Nianlin (7.72%), Anhui Huaying Smart IoT Fund Partnership (Limited Partnership) (7%) and Ningbo Huaying Xingzhi Investment Partnership (Limited Partnership) 0.14%).
3. SALIENT TERMS OF THE MOU The salient terms of the MOU are, amongst others, as follows:
(a) HWGB and ISIA are desirous of collaborating to manufacture and produce in vitro diagnostic products. (b) The Parties agree that further details of the collaboration including production matters and specifications shall be determined upon further discussion and shall be incorporated into the Definitive Agreement which shall then supersede the MOU.
4. RATIONALE OF THE MOU HWGB has a subsidiary in Indonesia, PT Ho Wah Genting which is capable of undertaking the manufacturing of in vitro diagnostic products at its facility located in Batam. With the collaboration with ISIA, HWGB will be able to manufacture and sell in vitro diagnostic products and expand market penetration globally.
5. DURATION OF THE MOU The MOU remains valid and effective for twelve (12) months from the date of the MOU or terminated by the execution of a definitive agreement which shall then supersede the MOU. Early termination is allowed by either party giving notice to terminate. In the event of termination, the term governing confidentiality and publicity of the MOU shall remain binding and enforceable notwithstanding the termination of the MOU.
6. FINANCIAL EFFECTS OF THE MOU The MOU is not expected to have any material effect on the earnings per share, net assets per share, gearing, share capital and substantial shareholders’ shareholding of the Company for the financial year ending 31 December 2021. Should the business materialize, it is expected to contribute positively to the future earnings of the Group.
7. RISK FACTORS The Company does not expect any material risk arising from the MOU as further details of the collaboration including production matters and specifications shall be determined upon further discussion.
8. STATEMENT BY DIRECTORS The Board of Directors of the Company, having taken into consideration all aspects of the MOU, is of the opinion that the MOU is in the best interest of HWGB and the Group.
9. APPROVALS REQUIRED The MOU is not subject to the approval of the shareholders of the Company.
10. DOCUMENTS AVAILABLE FOR INSPECTION The MOU is available for inspection at the Registered Office of the Company at Wisma Ho Wah Genting, 1st Floor, No. 35, Jalan Maharajalela, 50150 Kuala Lumpur during normal office hours on Mondays to Fridays (except for public holidays) for a period of three (3) months from the date of this announcement.
This announcement is dated 11 January 2021. |
Type | Announcement | Subject | NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS)
FUND RAISING | Description | HO WAH GENTING BERHAD ("HWGB" OR THE "COMPANY")PROPOSED PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN HWGB, REPRESENTING UP TO 10% OF THE TOTAL NUMBER OF ISSUED SHARES IN HWGB ("PROPOSED PRIVATE PLACEMENT") | On behalf of the Board of Directors of HWGB, AmInvestment Bank Berhad wishes to announce that the Company proposes to undertake the Proposed Private Placement.
Please refer to the attachment for further details of the Proposed Private Placement.
This announcement is dated 12 January 2021. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3120676
|
|
|
|
|
|
|
|
|
|
|
|
发表于 17-3-2022 11:17 AM
|
显示全部楼层
| 1. Details of Corporate Proposal | Involve issuance of new type/class of securities ? | No | Types of corporate proposal | Private Placement | Details of corporate proposal | PRIVATE PLACEMENT OF NEW ORDINARY SHARES IN HO WAH GENTING BERHAD ("HWGB"), REPRESENTING UP TO 10% OF THE TOTAL NUMBER OF ISSUED SHARES IN HWGB ("PRIVATE PLACEMENT") | No. of shares issued under this corporate proposal | 19,307,000 | Issue price per share ($$) | Malaysian Ringgit (MYR) 0.2300 | Par Value($$) (if applicable) | Malaysian Ringgit (MYR) 0.000 | | Latest issued share capital after the above corporate proposal in the following | Units | 638,869,891 | Issued Share Capital ($$) | Malaysian Ringgit (MYR) 152,938,266.550 | Listing Date | 22 Dec 2021 |
|
|
|
|
|
|
|
|
|
|
|
|
发表于 6-9-2022 08:50 AM
|
显示全部楼层
Type | Announcement | Subject | MEMORANDUM OF UNDERSTANDING | Description | MEMORANDUM OF UNDERSTANDING ENTERED INTO BETWEEN HWG FINTECH PROPERTY SDN BHD (HWG FINTECH PROPERTY) AND TERRAIN KOREA CO. LTD. (COMPANY NO. 727-86-00924) (TERRAIN KOREA) FOR THE APPOINTMENT OF TERRAIN KOREA AS AGENT TO PROMOTE AND MARKET IN KOREA 11 UNITS OF CONDOMINIUM IN ISKANDAR RESIDENCES. | 1. INTRODUCTION The Board of Directors of Ho Wah Genting Berhad (“HWGB” or “Company”) wishes to announce that its indirect wholly-owned subsidiary, HWG Fintech Property had on 5 September 2022 entered into a Memorandum of Understanding (“MOU”) with Terrain Korea Co., Ltd (hereinafter known as the “Parties”) to establish a basis of appointment of Terrain Korea as agent to promote and market in Korea 11 units of condominium in Iskandar Residences at No 6, Persiaran Medini Utara 3, Bandar Medini Iskandar, 79250 Iskandar Puteri, Johor Darul Takzim (“Product”) to be owned by HWG Fintech Property.
2. INFORMATION ON TERRAIN KOREA CO., LTD Terrain Korea Co., Ltd, incorporated in South Korea, is principally involved in business facilities management and business support services; rental and leasing activities/real estate activities.
The directors and shareholders are: Director | Shareholder | No. of shares held | % of shareholding | Kang Ki Bong | Kang Ki Bong | 20,000 | 100 |
| Total |
| 100% |
3. SALIENT TERMS OF THE MOU The salient terms of the MOU are, amongst others, as follows: a) Terrain Korea will promote HWG Fintech Property Product in South Korea. b) Terrain Korea will market HWG Fintech Property Product in South Korea.
The Parties shall execute an appointment letter to set out the details of the appointment, including the Parties’ rights, obligations and the terms should the appointment materialize.
4. RATIONALE OF THE MOU The MOU is entered into to set up the preliminary principal terms and conditions of mutual collaboration in relation to promoting and marketing the 11 units of condominium located at Iskandar Residence on a non-exclusive basis in South Korea.
5. DURATION OF THE MOU The MOU shall continue in force for a period of twelve (12) months from the date of the MOU (“Validity Period”) unless otherwise terminated on the earlier of: a) the execution of the appointment letter or such other agreement which shall then supersede the MOU; or
b) either party entitled to terminate the MOU by giving seven (7) day notice to each other about their intention;
c) In the absence of appointment letter or any form of agreement entered into by the Parties, the MOU shall lapse twelve (12) months from the date of the MOU.
d) without notice, (i) upon the institution by or against either party of insolvency, receivership or bankruptcy proceedings or any other proceedings for the settlement of either party's debts, (ii) upon either party making an assignment for the benefit of creditors, (iii) upon either party's dissolution or ceasing to do business, or (iv) material breach of its obligation under the MOU.
6. FINANCIAL EFFECTS OF THE MOU The MOU is not expected to have any material effect on the earnings per share, net assets per share, gearing, share capital and substantial shareholders’ shareholding of the Company for the financial year ending 30 April 2023. Should the business materialize, it is expected to contribute positively to the future earnings of the Group.
7. RISK FACTORS The Company does not expect any material risk arising from the MOU as the MOU is non-binding and is not intended to constitute a legally binding or enforceable agreement or commitment on either Party.
8. STATEMENT BY DIRECTORS The Board of Directors of the Company, having taken into consideration all aspects of the MOU, is of the opinion that the MOU is in the best interest of HWGB.
9. APPROVALS REQUIRED The MOU is not subject to the approval of the shareholders of the Company.
10. DOCUMENTS AVAILABLE FOR INSPECTION The MOU is available for inspection at the Registered Office of the Company at Wisma Ho Wah Genting, 1st Floor, No. 35, Jalan Maharajalela, 50150 Kuala Lumpur during normal office hours on Mondays to Fridays (except for public holidays) for a period of three (3) months from the date of this announcement.
This announcement is dated 5 September 2022.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 7-9-2022 09:36 AM
|
显示全部楼层
Type | Announcement | Subject | MEMORANDUM OF UNDERSTANDING | Description | ADDITIONAL INFORMATION ON MEMORANDUM OF UNDERSTANDING ENTERED INTO BETWEEN HWG FINTECH PROPERTY SDN BHD ("HWG FINTECH PROPERTY") AND TERRAIN KOREA CO. LTD. (COMPANY NO. 727-86-00924) ("TERRAIN KOREA") FOR THE APPOINTMENT OF TERRAIN KOREA AS AGENT TO PROMOTE AND MARKET IN KOREA 11 UNITS OF CONDOMINIUM IN ISKANDAR RESIDENCES | Unless otherwise stated, abbreviations and definitions used throughout this announcement shall be the same as those previously defined in the previous announcement dated 5 September 2022.
Reference is made to the Company’s announcement released on 5 September 2022 on the MOU with Terrain Korea to establish a basis of appointment of Terrain Korea as agent to promote and market in Korea 11 units of condominium in Iskandar Residences to be owned by HWG Fintech Property.
The Company would like to further inform that the proposed appointment of Terrain Korea is for promoting and marketing of the said 11 units of condominium for rental purposes.
This announcement is dated 6 September 2022.
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 2-10-2022 05:00 PM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
31 Jul 2022 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 31 Jul 2022 | 31 Jul 2021 | 31 Jul 2022 | 31 Jul 2021 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 145,235 | 119,887 | 145,235 | 119,887 | | 2 | Profit/(loss) before tax | 4,497 | -175 | 4,497 | -175 | | 3 | Profit/(loss) for the period | 3,174 | -674 | 3,174 | -674 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 3,175 | -689 | 3,175 | -689 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.50 | -0.11 | 0.50 | -0.11 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.1200 | 0.1100
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 5-3-2024 03:27 PM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
31 Dec 2023 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2022 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 49,035 | 0 | 255,223 | 0 | | 2 | Profit/(loss) before tax | -2,838 | 0 | 3,865 | 0 | | 3 | Profit/(loss) for the period | -2,566 | 0 | 1,157 | 0 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | -2,566 | 0 | 1,192 | 0 | | 5 | Basic earnings/(loss) per share (Subunit) | -1.44 | 0.00 | 0.67 | 0.00 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.00 | 0.00 | 0.00 | 0.00 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.4300 | 0.4500
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 7-3-2024 07:43 AM
|
显示全部楼层
Type | Announcement | Subject | OTHERS | Description | CONDITIONAL SHARE SALE AGREEMENT IN RELATION TO THE PROPOSED ACQUISITION OF 275,000 ORIDNARY SHARES REPRESENTING 55% EQUITY INTEREST IN ADVANCED APOTHEKE SDN BHD | The Board of Directors of Ho Wah Genting Berhad (“HWGB” or “Company”) wishes to announce that HWGB's wholly-owned subsidiary, HWGB Capital Sdn Bhd (formerly known as HWG Fintech Capital Sdn Bhd) had on 6 March 2024 entered into a Conditional Share Sale Agreement with Madam Leong Oi Heng (“Vendor”) for the proposed acquisition of 275,000 ordinary shares representing 55% equity interest in in Advanced Apotheke Sdn Bhd for a total cash consideration of Ringgit Malaysia Two Million and Four Hundred Thousand (RM2,400,000) Only.
Kindly refer to the attach file for further information of the announcement.
This announcement is dated 6 March 2024. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3428551
|
|
|
|
|
|
|
|
|
|
|
|
发表于 1-9-2024 02:35 PM
|
显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30 Jun 2024 |
| | INDIVIDUAL PERIOD | CUMULATIVE PERIOD | CURRENT YEAR QUARTER | PRECEDING YEAR
CORRESPONDING
QUARTER | CURRENT YEAR TO DATE | PRECEDING YEAR
CORRESPONDING
PERIOD | 30 Jun 2024 | 30 Jun 2023 | 30 Jun 2024 | 30 Jun 2023 | $$'000 | $$'000 | $$'000 | $$'000 |
| 1 | Revenue | 105,436 | 58,625 | 162,911 | 99,314 | | 2 | Profit/(loss) before tax | 2,424 | 2,099 | 2,794 | 1,810 | | 3 | Profit/(loss) for the period | 1,256 | 1,289 | 1,046 | 561 | | 4 | Profit/(loss) attributable to ordinary equity holders of the parent | 1,256 | 1,289 | 1,046 | 596 | | 5 | Basic earnings/(loss) per share (Subunit) | 0.61 | 0.19 | 0.51 | 0.09 | | 6 | Proposed/Declared dividend per share (Subunit) | 0.61 | 0.19 | 0.51 | 0.09 |
|
| AS AT END OF CURRENT QUARTER | AS AT PRECEDING FINANCIAL YEAR END | 7
| Net assets per share attributable to ordinary equity holders of the parent ($$) | 0.4400 | 0.4300
|
|
|
|
|
|
|
|
|
|
|
|
|
发表于 5-9-2024 11:20 AM
|
显示全部楼层
Type | Announcement | Subject | NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS)
FUND RAISING | Description | HO WAH GENTING BERHAD ("HWGB" OR THE "COMPANY")PROPOSED NOTES ISSUE | On behalf of the Board of Directors of HWGB (“Board”), Kenanga Investment Bank Berhad (“Kenanga IB”) wishes to announce that the Company proposes to undertake the proposed issuance of redeemable convertible notes (“Notes”) with an aggregate principal amount of up to RM60.00 million, which will mature on the date falling 36 months from the closing date of the first sub-tranche of the Tranche 1 Notes (as defined herein) (“Proposed Notes Issue”).
Please refer to the attachment below for further details.
This announcement is dated 26 August 2024. |
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3476786
|
|
|
|
|
|
|
|
|
|
| |
 本周最热论坛帖子
|
1779 
26
